94 related articles for article (PubMed ID: 25410889)
1. Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma.
Reitman ZJ
Pharmacogenomics; 2014 Sep; 15(13):1639-41. PubMed ID: 25410889
[No Abstract] [Full Text] [Related]
2. Over-expression of wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas.
Liang C; Guo E; Lu S; Wang S; Kang C; Chang L; Liu L; Zhang G; Wu Z; Zhao Z; Ma S; Wang L; Jiao BH
Brain Res; 2012 Mar; 1444():65-75. PubMed ID: 22325093
[TBL] [Abstract][Full Text] [Related]
3. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
Zhang L; Chen LH; Wan H; Yang R; Wang Z; Feng J; Yang S; Jones S; Wang S; Zhou W; Zhu H; Killela PJ; Zhang J; Wu Z; Li G; Hao S; Wang Y; Webb JB; Friedman HS; Friedman AH; McLendon RE; He Y; Reitman ZJ; Bigner DD; Yan H
Nat Genet; 2014 Jul; 46(7):726-30. PubMed ID: 24880341
[TBL] [Abstract][Full Text] [Related]
4. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.
Nikbakht H; Panditharatna E; Mikael LG; Li R; Gayden T; Osmond M; Ho CY; Kambhampati M; Hwang EI; Faury D; Siu A; Papillon-Cavanagh S; Bechet D; Ligon KL; Ellezam B; Ingram WJ; Stinson C; Moore AS; Warren KE; Karamchandani J; Packer RJ; Jabado N; Majewski J; Nazarian J
Nat Commun; 2016 Apr; 7():11185. PubMed ID: 27048880
[TBL] [Abstract][Full Text] [Related]
5. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
[TBL] [Abstract][Full Text] [Related]
7. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
[TBL] [Abstract][Full Text] [Related]
8. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255
[TBL] [Abstract][Full Text] [Related]
9. WIP1 phosphatase at the crossroads of cancer and aging.
Le Guezennec X; Bulavin DV
Trends Biochem Sci; 2010 Feb; 35(2):109-14. PubMed ID: 19879149
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
11. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
[TBL] [Abstract][Full Text] [Related]
12. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
[TBL] [Abstract][Full Text] [Related]
13. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
Fuku T; Semba S; Yutori H; Yokozaki H
Pathol Int; 2007 Sep; 57(9):566-71. PubMed ID: 17685927
[TBL] [Abstract][Full Text] [Related]
14. [Function of Proto-oncogene Product PPM1D and Development of PPM1D Inhibitors for Cancer Chemotherapy].
Kamada R; Chuman Y; Kozakai Y; Sakaguchi K
Seikagaku; 2015 Oct; 87(5):531-8. PubMed ID: 26638620
[No Abstract] [Full Text] [Related]
15. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
Park JY; Song JY; Kim HM; Han HS; Seol HS; Jang SJ; Choi J
Int J Biochem Cell Biol; 2012 Jun; 44(6):896-904. PubMed ID: 22405851
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the Wip1 phosphatase and its effects on the stress response.
Lowe J; Cha H; Lee MO; Mazur SJ; Appella E; Fornace AJ
Front Biosci (Landmark Ed); 2012 Jan; 17(4):1480-98. PubMed ID: 22201816
[TBL] [Abstract][Full Text] [Related]
17. Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1.
Yamaguchi H; Durell SR; Feng H; Bai Y; Anderson CW; Appella E
Biochemistry; 2006 Nov; 45(44):13193-202. PubMed ID: 17073441
[TBL] [Abstract][Full Text] [Related]
18. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
[TBL] [Abstract][Full Text] [Related]
19. Wip1 phosphatase in breast cancer.
Emelyanov A; Bulavin DV
Oncogene; 2015 Aug; 34(34):4429-38. PubMed ID: 25381821
[TBL] [Abstract][Full Text] [Related]
20. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
Pärssinen J; Alarmo EL; Karhu R; Kallioniemi A
Cancer Genet Cytogenet; 2008 Apr; 182(1):33-9. PubMed ID: 18328948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
